Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

• Status: Completed
• Trial end date: 2003-09-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglobulinemia. Subjects are treated every 21 days and receive a total of 12 infusions: for the first 3 infusions subjects receive GAMMAGARD S/D to ensure a steady-state and to acquire data with a licensed product; for the remaining 9 infusions subjects receive IGIV, 10% TVR Solution.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baxalta now part of Shire; Baxalta US Inc.
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Pharmaceutical Solutions; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

Subjects will be eligible for study entry if they:

• are at least 18 years old

• have a form of primary immunodeficiency (PID) as described by Rosen et al, 1999 16 manifesting as agammaglobulinemia (X-linked) or hypogamma-globulinemia (common variable immunodeficiency), requiring immunoglobulin replacement therapy

• have had regular treatment for at least three months with either intravenous immunoglobulin preparations or immunoglobulin preparations for intramuscular use given subcutaneously

• have serum IgG levels greater than or equal to 5 g/L as determined by the local laboratory at screening

• if female of childbearing potential, agree to employ adequate birth control measures during the study

• have given written informed consent

Exclusion Criteria:

Subjects will not be eligible for study entry if they:

• had severe adverse reactions to treatment with immunoglobulin preparations during the last three treatments before inclusion into the study

• suffer from documented selective IgA deficiency with antibodies against IgA

• have an acute infection that requires intravenous antibiotic treatment (Last treatment day should be seven days before study entry.)

• are known to be infected with HIV, HCV, or HBV

• are at high risk of contracting blood-borne viral infections through parenteral drug abuse or life style

• suffer from congestive heart failure and receive on-demand treatment with furosemide

• show renal dysfunction defined as serum creatinine greater than or equal to 1.5 mg/dL at baseline visit

• received another investigational drug in the three weeks preceding study entry

• in case of females, are pregnant or nursing mothers